Long-term Frexalimab Treatment Modulates the Activity of Immune Networks (EAN 2026) - Jun 12, 2026 - Abstract #EPO-0780; Pres time: Jun 29, 2026; 12:50 PM - 12:55 PM; Location: B5; P2 | "Long-term frexalimab treatment exerts comprehensive immunomodulatory effects by downregulating inflammatory mediators associated with disease progression. These findings support understanding of frexalimab's mechanism of action, which targets immune networks involving adaptive and innate immunity, and holds the potential to mitigate acute and chronic neuroinflammation in MS."
IO biomarker • CNS Disorders • Inflammation • Multiple Sclerosis • CD27 • CD40LG • CSF1R • CXCL13 • GZMA
|
|
B. Djukic 1; R. Gandhi 1; G. Boldina 2; V. Truong 3; N. Ternes 4; B. Zhang 1; M. Levit 1; P. Krishnaswami 1; S. S. Geertsen 1; S. Saubadu 5; P. Truffinet 5; H. Wiendl 6; T. Chitnis 7; A. Bar-Or 8
|